KCM
CLCD

Kornitzer Capital Management’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

Kornitzer Capital Management’s Portfolio CLCD Stock Details CLCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-10,000
Closed -$381K – 495
2016
Q3 		$381K Buy
+10,000
New +$148K 0.01% 426

Other funds holding CLCD

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Kornitzer Capital Management's CLCD Position: Q4 2016 in Review

Kornitzer Capital Management sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q4 2016, closing a stake of 10,000 shares — an estimated $381K sold.

Kornitzer Capital Management first reported a position in CLCD in Q3 2016 and held it in 1 quarter. The position peaked at $381K in Q3 2016. 76 funds tracked by Wall St. Rank hold CLCD as of Q4 2016.

  • Kornitzer Capital Management reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Kornitzer Capital Management sold 10,000 CoLucid Pharmaceuticals, Inc. shares in Q4 2016, an estimated $381K.
  • Kornitzer Capital Management first reported a position in CoLucid Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Kornitzer Capital Management's CoLucid Pharmaceuticals, Inc. position peaked at $381K in Q3 2016.
  • 76 funds tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q4 2016.

Based on Kornitzer Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.